Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
In Vivo: CRISPR/Cas9 Gene Editing Shows Promise in Prostate Cancer Treatment
/in CRISPR, Preclinical Research/by MaxIn Vitro: Targeted Cancer Therapy with 4armPEG-DD: A Precision Approach for Prostate Cancer
/in Delivery, Preclinical Research/by MaxIn vivo: Menadione Sodium Bisulfite (vitamin K3) as a Pro-Oxidant Therapy for Prostate Cancer
/in Preclinical Research/by MaxPost-hoc of ARASENS for metastatic hormone sensitive prostate cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxDarolutamide Plus ADT and Docetaxel Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in ARASENS Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxDarolutamide Plus ADT: A Great Treatment Option for Metastatic Hormone-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxFirst-in-Class Targeted microRNA Therapy Slows Cancer Tumor Growth
/in Preclinical Research/by Max